Related Experiment Video
Updated: Jun 19, 2026

Augmented Reality Navigation-Guided Core Decompression for Osteonecrosis of Femoral Head
Published on: April 12, 2022
Treatment of sickle cell disease's hip necrosis by core decompression: a prospective case-control study
M Mukisi-Mukaza1, O Manicom, C Alexis
1Orthopaedics-Traumatology Unit, Pointe-à-Pitre University Hospital Center (UHC), CHU de Pointe-à-Pitre, 97159 Guadeloupe, France. mukisi@only.fr
Insights
Core decompression significantly improved pain and function for sickle-cell disease avascular necrosis of the femoral head (ONFH). This treatment delays the need for total hip arthroplasty compared to conservative management.
Area of Science:
- Orthopedic Surgery
- Hematology
- Regenerative Medicine
Background:
- Sickle-cell disease avascular necrosis of the femoral head (ONFH) affects young patients, posing risks with total arthroplasty and high implant costs.
- Evaluating core decompression's efficacy is crucial for managing ONFH in sickle-cell disease patients.
Purpose of the Study:
- To compare the clinical and radiological outcomes of core decompression versus conservative treatment for sickle-cell disease ONFH.
- To assess core decompression's ability to relieve pain, improve function, and delay the need for total hip arthroplasty.
Main Methods:
- Prospective study of 42 patients (42 hips) treated with core decompression and 16 patients (23 hips) in a non-operated control group.
- Evaluation based on pain scale, Merle d'Aubigné-Postel (MAP) functional score, radiological progression (Koo and Kim Index), and time to total arthroplasty.
- Study conducted from 1994 to 2008 with a follow-up of 11.3+/-1.8 years for the operated group and 13.4+/-0.5 years for the non-operated group.
Main Results:
- Core decompression resulted in significant pain reduction and MAP score improvement in 93% of operated hips (p<0.0001).
- The operated group experienced a significant delay in total arthroplasty (7.4+/-2.7 years) compared to the non-operated group (2.6+/-2.4 years, p=0.0007).
- The Koo and Kim Index showed improvement in the operated group (p=0.0002) and degradation in the non-operated group (p=0.002).
Conclusions:
- Core decompression offers superior clinical and radiological outcomes compared to surgical abstention for sickle-cell disease ONFH.
- The procedure effectively delays the need for total hip arthroplasty, providing a significant benefit of approximately 4.8 years.
- Core decompression is a valid and recommended treatment option, particularly in resource-limited settings where sickle-cell disease complications are prevalent.
Introduction:
The young age of patients, total arthroplasties complications risks, and implant costs justify evaluation of the results of core decompression in the treatment of sickle-cell disease avascular necrosis of the femoral head (ONFH).
Hypothesis:
In sickle-cell disease necrosis, core decompression offers good relief from pain and delays the use of total arthroplasty in comparison to a conservatively treated control group by a simple non-weight bearing protocol.
Materials And Methods:
From 1994 to 2008, among 215 drepanocytic adults, 42 patients (22 genotype SS, 20 genotype SC; 15 men, 27 women) presented symptomatic ONFH. We report the data from a prospective study of two patients' groups: a non-operated group (16 patients aged 36.5+/-6.5 years, 23 hips) and an operated group (26 patients aged 30.3+/-2.8 years, 42 hips). The results were considered on the basis of change in clinical status according to the numeric evaluation of pain scale, the functional score of Merle d'Aubigné-Postel (MAP), the radiological progression of lesions, and the time delay to total arthroplasty.
Results:
Twenty-three hips were conservatively treated by discharge (a pair of canes). After a follow-up period of 13.4+/-0.5 years, no pain improvement was noted (p=0.76), and MAP score was unchanged (p=0.27). Out of 23 hips managed by discharge, 9 stage IV hips (degenerative arthritis, 39.1%) underwent arthroplasty after an average delay of 2.6+/-2.4 years. Forty-two hips were treated by core decompression. The duration of follow-up was 11.3+/-1.8 years. Postoperatively, pain reduction and MAP score improvement were significant in 39 out of 42 hips (93%, p<0.0001). Twenty-nine out of these 42 hips had a favorable evolution. Ten hips (23.8%) progressed to total arthroplasty, after a period of 7.4+/-2.7 years, longer than the one of the non-operated group (p=0.0007). By comparing the two groups (operated and non-operated), the benefit of core decompression appeared very significant (p<0.0001). In addition to allocating patients osteonecrosis stages, the Koo and Kim Index estimated the severity and evolution of necrotic lesions in both groups. It indicated decline in the non-operated group (p=0.002) and improvement for operated patients (p=0.0002).
Discussion:
Core decompression had a favorable clinical and radiological outcome superior to surgical abstention. Stages I and II ONFH remained stable after drilling, necessitating no arthroplasty (considered as a failure of drilling). The Koo and Kim Index above 30 degrees in the non-operated group was a significant indicator of lesions degradation (p=0.002). In addition to the indolence obtained by core decompression, the benefit of drilling was manifested by the prolonging the adjournment before arthroplasty end-point. It was respectively 7.4+/-2.7 years in the operated group versus 2.6+/-2.4 years in the non-operated group (difference of 4.8 years, p<0.01).
Conclusion:
The technique of core decompression remains a valid option place in the treatment sickle-cell disease avascular necrosis of the femoral head (ONFH). It may be especially recommended in under-equipped regions where drepanocytosis and its osteo-articular complications are frequent.
Level Of Evidence:
Level III case-control therapeutic study.
Related Concept Videos
Peripheral Artery Disease IV: Nursing Management
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Peripheral Artery Disease V: Postoperative Nursing Management
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Acute Kidney Injury IV: Diagnostic Studies and Prevention
